CORRECTING and REPLACING Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc.
The corrected release reads:
CATALENT SIGNS AGREEMENT TO ACQUIRE JUNIPER PHARMACEUTICALS, INC.
“Juniper’s proven solutions and capabilities will further support Catalent’s strategic goal to be the most comprehensive partner for pharmaceutical innovators,” commented
Juniper’s nearly 150 employees have deep scientific expertise in formulation development, and supply, and will augment Catalent’s current portfolio of solid-state screening, preformulation, formulation, analytical, and bioavailability enhancement solutions, including development of spray-dried dispersions, with integrated development, analytical, and clinical manufacturing co-located in its
Like
In 2016,
The Acquisition
Under its acquisition agreement with Juniper, a subsidiary of
Important Information
In connection with the proposed acquisition, a subsidiary of
About
Juniper Pharmaceuticals™ is a trademark of
CRINONE® is a registered trademark of Merck KGaA, Darmstadt,
About
More products. Better treatments. Reliably supplied.™
Cautionary Note Concerning Forward-Looking Statements
This release contains both historical and forward-looking statements, including concerning the tender offer for and merger with Juniper. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified because they relate to the topics set forth above or by the use of statements that include phrases such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “project,” “foresee,” “likely,” “may,” “will,” “would” or other words or phrases with similar meanings. Similarly, statements that describe Catalent’s objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent’s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: regulatory actions that may delay or interfere with the closing of the acquisition or result in other changes to Catalent’s business; other unanticipated events that may prevent a closing of the acquisition or may make it more difficult to realize the anticipated benefits of the transaction; participation in a highly competitive market and increased competition may adversely affect the business of
View source version on businesswire.com: https://www.businesswire.com/news/home/20180703005086/en/
Media:
[email protected]
or
NEPR
[email protected]
or
Investors:
[email protected]
Source:
Individual market costs remain steady because of reinsurance program
OPINION: No flood insurance? Here’s what you can expect
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News